Research Article
Systematic Characterization of Prognostic Values of Peroxiredoxin Family in Gastric Cancer
Table 5
Association between PRDX expression and OS in GC patients with different treatment strategies.
| PRDXs | Treatment strategies | Cases | Low | High | HR (95% CI) | value |
| PRDX1 | Surgery alone | 380 | 190 | 190 | 0.76 (0.57–1.01) | 0.057 | 5-FU-based adjuvant | 153 | 76 | 77 | 1.21 (0.86–1.71) | 0.268 | Other adjuvants | 76 | 38 | 38 | 0.67 (0.27–1.64) | 0.374 |
| PRDX2 | Surgery alone | 380 | 190 | 190 | 0.72 (0.54–0.96) | 0.025 | 5-FU-based adjuvant | 153 | 76 | 77 | 0.68 (0.48–0.97) | 0.030 | Other adjuvants | 76 | 38 | 38 | 0.61 (0.25–1.50) | 0.276 |
| PRDX3 | Surgery alone | 380 | 190 | 190 | 0.74 (0.55–0.99) | 0.038 | 5-FU-based adjuvant | 153 | 76 | 77 | 1.20 (0.85–1.69) | 0.296 | Other adjuvants | 76 | 38 | 38 | 0.94 (0.39–2.26) | 0.883 |
| PRDX4 | Surgery alone | 380 | 190 | 190 | 0.85 (0.64–1.14) | 0.275 | 5-FU-based adjuvant | 153 | 76 | 77 | 0.78 (0.56–1.11) | 0.164 | Other adjuvants | 76 | 38 | 38 | 1.01 (0.42–2.43) | 0.990 |
| PRDX5 | Surgery alone | 380 | 191 | 189 | 0.82 (0.62–1.10) | 0.187 | 5-FU-based adjuvant | 34 | 17 | 17 | 0.94 (0.38–2.33) | 0.893 | Other adjuvants | 76 | 38 | 38 | 0.48 (0.19–1.20) | 0.110 |
| PRDX6 | Surgery alone | 380 | 190 | 190 | 1.04 (0.78–1.38) | 0.795 | 5-FU-based adjuvant | 153 | 76 | 77 | 0.98 (0.70–1.38) | 0.913 | Other adjuvants | 76 | 38 | 38 | 1.16 (0.48–2.80) | 0.738 |
|
|